• Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

    المصدر: Nasdaq GlobeNewswire / 11 سبتمبر 2024 07:00:00   America/New_York

    SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.

    Stifel 2024 Virtual Immunology and Inflammation Summit
    Date: Wednesday, September 18, 2024
    Format: 1x1 meetings

    About Eliem Therapeutics, Inc.
    Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.

    Investors
    Chris Brinzey
    ICR Westwicke
    chris.brinzey@westwicke.com
    339-970-2843


    Primary Logo

شارك على،